"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 8 | 2 | 10 |
| 2000 | 1 | 1 | 2 |
| 2001 | 5 | 1 | 6 |
| 2002 | 3 | 5 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 6 | 0 | 6 |
| 2005 | 4 | 0 | 4 |
| 2006 | 8 | 2 | 10 |
| 2007 | 6 | 1 | 7 |
| 2008 | 4 | 0 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 11 | 0 | 11 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 9 | 4 | 13 |
| 2015 | 7 | 0 | 7 |
| 2016 | 2 | 7 | 9 |
| 2017 | 13 | 2 | 15 |
| 2018 | 12 | 4 | 16 |
| 2019 | 13 | 7 | 20 |
| 2020 | 18 | 7 | 25 |
| 2021 | 9 | 5 | 14 |
| 2022 | 5 | 21 | 26 |
| 2023 | 6 | 23 | 29 |
| 2024 | 30 | 10 | 40 |
| 2025 | 31 | 5 | 36 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025 Dec 09; 9(23):6047-6058.
-
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv. 2025 Nov 11; 9(21):5460-5472.
-
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.
-
Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b. Cancer Immunol Res. 2025 Nov 03; 13(11):1732-1748.
-
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025 Oct 28; 9(20):5249-5262.
-
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025 Oct 14; 9(19):5070-5084.
-
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer Immunol Res. 2025 Oct 01; 13(10):1576-1590.
-
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer Immunol Res. 2025 Oct 01; 13(10):1591-1608.
-
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia. 2025 Dec; 39(12):3004-3014.
-
Next-generation multiplex-edited CAR-NK cells: more edits, more power? J Immunother Cancer. 2025 Sep 15; 13(9).